Dashboard
1
Poor Management Efficiency with a low ROCE of 11.05%
- The company has been able to generate a Return on Capital Employed (avg) of 11.05% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
3
Poor long term growth as Net Sales has grown by an annual rate of -1.89% and Operating profit at -5.50% over the last 5 years
4
Flat results in Jun 26
5
With ROE of 6.32%, it has a attractive valuation with a 0.89 Price to Book Value
6
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CNY 6,745 Million (Mid Cap)
14.00
NA
2.32%
-0.47
6.32%
1.07
Revenue and Profits:
Net Sales:
843 Million
(Quarterly Results - Jun 2026)
Net Profit:
135 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
11.11%
0%
11.11%
6 Months
-9.43%
0%
-9.43%
1 Year
-30.54%
0%
-30.54%
2 Years
23.42%
0%
23.42%
3 Years
8.87%
0%
8.87%
4 Years
26.19%
0%
26.19%
5 Years
12.22%
0%
12.22%
Cisen Pharmaceutical Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-1.89%
EBIT Growth (5y)
-5.50%
EBIT to Interest (avg)
94.29
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.39
Sales to Capital Employed (avg)
0.62
Tax Ratio
13.94%
Dividend Payout Ratio
37.40%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
10.17%
ROE (avg)
7.85%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
0.89
EV to EBIT
10.29
EV to EBITDA
6.41
EV to Capital Employed
0.79
EV to Sales
0.79
PEG Ratio
NA
Dividend Yield
2.78%
ROCE (Latest)
7.72%
ROE (Latest)
6.32%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
842.80
819.60
2.83%
Operating Profit (PBDIT) excl Other Income
71.10
105.20
-32.41%
Interest
0.10
0.40
-75.00%
Exceptional Items
44.00
15.50
183.87%
Consolidate Net Profit
134.80
86.70
55.48%
Operating Profit Margin (Excl OI)
20.80%
72.50%
-5.17%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 2.83% vs -9.95% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 55.48% vs -22.24% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
3,419.90
3,953.80
-13.50%
Operating Profit (PBDIT) excl Other Income
457.70
638.70
-28.34%
Interest
1.70
7.60
-77.63%
Exceptional Items
39.70
10.50
278.10%
Consolidate Net Profit
425.60
514.90
-17.34%
Operating Profit Margin (Excl OI)
74.90%
104.60%
-2.97%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -13.50% vs -10.64% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -17.34% vs -2.00% in Dec 2024
About Cisen Pharmaceutical Ltd. 
Cisen Pharmaceutical Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






